<SEC-DOCUMENT>0001610717-26-000051.txt : 20260219
<SEC-HEADER>0001610717-26-000051.hdr.sgml : 20260219
<ACCEPTANCE-DATETIME>20260219170421
ACCESSION NUMBER:		0001610717-26-000051
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260217
FILED AS OF DATE:		20260219
DATE AS OF CHANGE:		20260219

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Milligan Michael Lee
		CENTRAL INDEX KEY:			0001993953
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41802
		FILM NUMBER:		26655511

	MAIL ADDRESS:	
		STREET 1:		C/O NEUMORA THERAPEUTICS, INC.
		STREET 2:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neumora Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001885522
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				844367680
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		260 ARSENAL PLACE, SUITE 1
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(857) 760-0900

	MAIL ADDRESS:	
		STREET 1:		260 ARSENAL PLACE, SUITE 1
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RBNC Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210929
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-02-17</periodOfReport>

    <issuer>
        <issuerCik>0001885522</issuerCik>
        <issuerName>Neumora Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>NMRA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001993953</rptOwnerCik>
            <rptOwnerName>Milligan Michael Lee</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O NEUMORA THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>260 ARSENAL WAY, SUITE 1</rptOwnerStreet2>
            <rptOwnerCity>WATERTOWN</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02472</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>true</isOfficer>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>true</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2026-02-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1436</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.565</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>21034</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.</footnote>
    </footnotes>

    <remarks>Title: Chief Financial Officer &amp; Principal Accounting Officer</remarks>

    <ownerSignature>
        <signatureName>/s/ Michael Lee Milligan</signatureName>
        <signatureDate>2026-02-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
